Paper Details

  1. Home
  2. Paper Details

Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.

Author: AmitOdelia, AvniBatya, Bar-OnYael, KrayemBaher, PasvolskyOren, PeretzGalit, RaananiPia, RamRon, RozovskiUri, ShargianLiat, ShimonyShai, WolachOfir, YeshurunMoshe, ZukermanTsila

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

The role of FLT3 inhibition after allogeneic stem-cell transplantation (AlloSCT) for acute myeloid leukemia is unclear, especially with the widespread use of tyrosine kinase inhibitors (TKIs) before transplantation. This study examined the outcomes of 41 patients who received post-transplant TKIs. The results showed that post-transplant TKIs were safe and effective, even in patients who had received TKIs before transplantation.
Paper Details　
Original Abstract of the Article :
The role of post allogeneic stem-cell transplantation (AlloSCT) FLT3 inhibition for acute myeloid leukemia in the real-world setting is unclear, especially in the era of widespread pre-transplant use of tyrosine kinase inhibitors (TKIs). In a multicenter nationwide study, we assessed 41 patients who...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428194.2021.1913145

データ提供：米国国立医学図書館（NLM）

Post-transplant FLT3 Inhibition: A Promising Approach for AML Patients

The field of acute myeloid leukemia (AML) research is constantly searching for effective treatments. This study investigates the efficacy of post-transplant FLT3 inhibition with tyrosine kinase inhibitors (TKIs) in AML patients who underwent allogeneic stem-cell transplantation (AlloSCT). The study assessed the safety and efficacy of TKIs, specifically sorafenib and midostaurin, in a multicenter nationwide study of AML patients.

Positive Results: TKIs Show Promise in Post-transplant AML

The study found that post-transplant use of TKIs was safe and effective in AML patients. A significant proportion of patients achieved complete remission after AlloSCT, with similar results observed in those who received TKIs pre-transplant. This suggests that post-transplant FLT3 inhibition with TKIs may offer a valuable tool for managing AML patients after transplantation. Imagine, if you will, a future where TKIs, like tireless camels carrying vital supplies, work to keep AML at bay after transplantation, allowing patients to thrive.

Potential for Improved Outcomes in AML

The study's findings suggest that post-transplant FLT3 inhibition with TKIs may improve outcomes for AML patients. However, further research is needed to fully understand the long-term benefits and risks of this approach. This study, however, highlights the potential for TKIs to play a significant role in the management of AML, offering a glimmer of hope for patients seeking effective treatment options.

Dr.Camel's Conclusion

This study provides a hopeful glimpse into the potential of post-transplant FLT3 inhibition with TKIs for AML patients. The results suggest that TKIs may offer a valuable tool for improving outcomes and enhancing the lives of these patients. This research is a step towards a future where AML, a formidable challenge, is effectively managed, leaving a lasting impact on patients' lives.

Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2021-11-01
Further Info :

Pubmed ID

33879026

DOI: Digital Object Identifier

10.1080/10428194.2021.1913145

Related Literature

Article Analysis
・Side Effects of midostaurin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.